Extended Dosing With Eltrombopag for Severe Aplastic Anemia
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Background:
- Eltrombopag is a drug being tested for treating severe aplastic anemia. It can help improve
blood counts in these patients. However, researchers do not know how long the drug can and
should be taken for this type of anemia.
Objectives:
- To look at whether 6 months of treatment with eltrombopag can improve patient s blood
counts.
Eligibility:
- Individuals at least 2 years of age who are taking eltrombopag for severe aplastic anemia.
Design:
- Participants will take eltrombopag by mouth once a day for 6 months.
- Blood samples will be collected every 2 weeks for the first 6 months. Bone marrow
samples will be collected at 3 and 6 months. These samples will look at the effects of
the study drug on the marrow.
- Participants will continue to take the study drug for as long as it is effective and if
the side effects are not severe.